NCT06427590

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Healthy and Obese Subjects

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 Injection for Subcutaneous Use in Healthy and Obese Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Ascletis Pharma (China) Co., Limited · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This will be a phase I, randomized, double-blind, placebo-controlled, single dose escalation study. This study will be conducted in three periods: the screening period, the treatment period, and the follow-up period. This study aims to evaluate the pharmacokinetics and target engagement of ASC47 in healthy and obese subjects.

Conditions

• Chronic Weight Management

Interventions

Type	Name	Description
DRUG	ASC47	single subcutaneous injection of ASC47
DRUG	Matching placebo	single subcutaneous injection of Placebo

Timeline

• Start date: 2024-07-13
• Primary completion: 2024-12-31
• Completion: 2024-12-31
• First posted: 2024-05-24
• Last updated: 2025-05-11

Locations

1 site across 1 country: Australia